Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Chronicle Live
Chronicle Live
Health
Sam Volpe

Newcastle researchers get £2.7m for groundbreaking cancer trials which could reveal 'crucial' new treatments

Cancer researchers in Newcastle have been given £2.7m to run clinical trials to find exciting new treatments which could tackle the disease.

The funding for the city's Experimental Cancer Medicine Centre (ECMC) provides hope for people who might have been diagnosed with as yet untreatable forms of cancer. The research team has welcomed the funding boost as something which could help thousands.

The ECMC is a partnership between Newcastle University and the Newcastle Hospitals NHS Trust - and it is led by Prof Ruth Plummer, who also helped set up and runs the Sir Bobby Robson Cancer Trials Research Centre at the Freeman.

Read more: Grieving Jesmond widower's fight for better dementia care after years caring for wife

The funding - which totals £2.719,297 - will be used to support doctors and scientists to find "the cancer treatments of the future" to save the lives of children and adults. It comes from Cancer Research UK, the National Institute for Health and Care Research and the Little Princess Trust.

It will support the development of new treatments including immunotherapy, along with improvements to existing treatments. Prof Ruth Plummer said: "We are delighted Newcastle has secured this funding. Clinical trials are crucial to new and improved treatments becoming adopted as standard treatments by the NHS and this funding will allow us to further advance how we can treat cancer effectively.

Sir Bobby Robson Cancer Trials Centre director Professor Ruth Plummer has been made an MBE (Sir Bobby Robson Foundation / James Byrne)

"Thousands of patients have been provided with access to new drugs and therapies through the Newcastle ECMC and this funding will benefit people with cancer in the North East and beyond."

In the past, money like this from Cancer Research UK has helped develop groundbreaking drugs like tamoxifen which is now an essential breast cancer treatment which helps ensure two-thirds of those diagnosed with breast cancer this year are predicted to survive at least 20 years with the disease.

Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK, said: "We are proud to be supporting an expansion of our successful ECMC network, bringing together vast medical and scientific expertise to translate the latest scientific discoveries from the lab into the clinic.

"The ECMC network is delivering the cancer treatments of the future, bringing new hope to people affected by cancer. The trials taking place today will give the next generation the best possible chance of beating cancer."

READ NEXT:

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.